About iGenomX
iGenomX is a company based in San Diego (United States) founded in 2012 was acquired by Twist Bioscience in June 2021. iGenomX has raised $5.13 million across 2 funding rounds from investors including Twist Bioscience. iGenomX operates in a competitive market with competitors including Abcam, Stem Cell Technologies, GenScript, Sino Biological and RareCyte, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Igenomx International Genomics Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.13 M (USD)
in 2 rounds
-
Latest Funding Round
$2.11 M (USD), Series A
Apr 23, 2019
- Investors
-
Employee Count
Not available
-
Acquired by
Twist Bioscience
(Jun 30, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of iGenomX
iGenomX has successfully raised a total of $5.13M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.11 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in iGenomX
iGenomX has secured backing from 1 investor. Prominent investors backing the company include Twist Bioscience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Synthetic DNA is synthesized via a semiconductor-based platform.
|
Locked | Locked | Locked |
Investor details for iGenomX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by iGenomX
Investment portfolio details for iGenomX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - iGenomX
Detailed financials for iGenomX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Igenomx Comparisons
Peer comparison for iGenomX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of iGenomX
iGenomX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, GenScript, Sino Biological and RareCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological reagents and antibodies are developed for life science research.
|
|
| Locked | Locked | Locked |
Developer of cell culture media and ancillary reagents for life science research
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
Detailed competitors of iGenomX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Igenomx
Complete news archive for iGenomX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iGenomX
iGenomX was founded in 2012 and raised its 1st funding round 3 years after it was founded.
iGenomX is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
iGenomX is a funded company, having raised a total of $5.13M across 2 funding rounds to date.
iGenomX offers low-cost sample preparation technology capable of detecting all genetic variation. The tech was licensed from the laboratory of Dr. Daniel Salomon at the Scripps Research Institute. The low cost, fully automatable methodology centers around precisely controlling the polymerase enzyme to catalyze the formation of long-chain molecules by linking smaller molecular units, such as nucleotides with nucleic acids. This overcomes uncontrolled polymerization which causes amplification bias and error propagation, which leads to increased costs and reduced data quality.
iGenomX's top competitors include Abcam, Sino Biological and Paragon Genomics.
iGenomX has 1 investor. Key investors include Twist Bioscience.